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Spontaneous development of malignant phase hypertension in trans.
genic Ren-2 rats. Spontaneous development of malignant phase hyperten-
sion in TGR(mREN2)27 heterozygotes occurs as a consequence of
crossing TGR(mREN2)27 homozygotes with Edinburgh Sprague-Dawley
rats. Similarities to human malignant phase hypertension are seen with an
accelerated rise in blood pressure, fibrinoid necrosis of renal afferent
arterioles, renal failure and evidence of renin-angiotensin system activa-
tion. It appears that introduction of an additional genetic factor or factors
into a monogenic model of hypertension results in malignant phase
hypertension.
Malignant hypertension (MH) is a rare but important compli-
cation of human essential hypertension [1, 21. Clinical markers of
transformation to the accelerated phase include a rising blood
pressure, presumed pressure diuresis, renal failure and develop-
ment of grade III or IV retinopathy. Characteristic pathological
changes in the renal vasculature occur including myointimal
proliferation or 'onion skinning' with endothelial swelling and
fibrinoid necrosis [3, 41. Activation of the renal renin-angiotensin
system (RAS) is a presumed consequence of salt and water loss
combined with afferent renal vascular pathology. This may serve
to further increase blood pressure resulting in a vicious circle of
progressive renal damage and rising blood pressure.
Most animal models of MH to date have been limited by the
need for dietary, surgical or pharmacological intervention to
precipitate onset and this has made the study of both primary or
initiating factors and secondary events operating in malignant
hypertension difficult to study [5—71.
The transgenic rat line TGR(mREN2)27 develops hyperten-
sion as a consequence of introduction and expression of the
mouse Ren-2 renin gene into the Sprague-Dawley (SD) rat [8].
Blood pressure rises to a plateau at 10 weeks of age and
development of progressive left ventricular hypertrophy, arterial
medial thickening and glomeruloscierosis occurs with increasing
age [9}. Fibrinoid necrosis was not described in transgenic het-
erozygotes. However, the underlying pathogenesis of the hyper-
tension remains unclear.
The breeding of a colony of TGR(mREN2)27 heterozygotes in
Edinburgh using SD rats (Centre for Genome Research, Univer-
sity of Edinburgh) was associated with the spontaneous onset of a
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phenotypic change with the occurence of a fatal syndrome at 50 to
90 days of age. Features included a one to three day history of
polyuria, weight loss, dehydration, apathy, piloerection, seizures
and hemiplegia. Some similarities to human MH prompted this
study to characterize this as a potential animal model and to
identit' whether environmental or genetic factors may be respon-
sible.
Methods
Initially three transgenic heterozygote crosses were bred. Ho-
mozygote TGR(mREN2)27 rats (TGR#27), derived from a Han-
nover SD colony (Central Institute for Laboratory Animal Breed-
ing, Hannover, Germany) were crossed with (1) SD (Edinburgh)
obtained from the colony in the Centre for Genome Research, (2)
SD (Hannover) from the Central Institute for Laboratory Animal
Breeding (Hannover, Germany) and (3) Lewis rats from Harlan-
Olac (Bicester, Oxford).
All animals were housed in the same room with a 12:12 hour
light-dark cycle, controlled temperature (18 to 20°C), humidity
(45 to 65%), diet (0.32% sodium CRM diet, SDS, Witham, Essex,
UK) and ad libitum tap water to drink. An alternative standard rat
diet containing 0.2% sodium (CRM X) was prepared, and when
used was given from weaning.
Direct blood pressure monitoring using telemetry (Data Sci-
ences International, St. Paul, Minnesota, USA) allowed continu-
ous recording of mean blood pressure (MBP) in conscious,
unrestrained male rats starting from 46 to 50 days of age following
recovery from surgical implantation under halothane anaesthesia
[10, 11]. Indirect measurement of systolic blood pressures (SBP)
used a tail cuff plethysmography method (IITC Life Sciences)
under light halothane anaesthaesia. Student's t-test was used for
statistical analysis with a P value of less than 0.05 taken to be
significant.
Light microscopic examination of kidney, heart, brain and
mesenteric artery was performed after fixation of tissues in 4%
formal saline, wax embedding, sectioning (3 m) and staining
(hematoxylin and eosin, Martius Scarlett Blue, and periodic acid
schiff stains). Renal function was assessed by plasma creatinine
(Electro-nucleonics®). Plasma renin activity (PRA), angiotensin
II (Ang II) and aldosterone were assayed by specific radioimmu-
noassay [12—14]. Immunohistochemistry of fixed kidney sections
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Table 1. The incidence of the MH phenotype in male and female
transgenic heterozygotes maintained under the same environmental
conditions and on the same diet
Heterozygote cross Name
Incidence of MH phenotype
Male Female
TGR#27-Edin SD TGR/Edin 86/117 (73.5%) 83/158 (52.5%)
TGR#27-Han SD TGR/Han 7/39 (18%) 2/44 (4%)
TGR#27-Lewis TGR/Lew 0/35 (0%) 0/31 (0%)
was performed using a polyclonal rabbit anti-mouse renin anti-
body, which cross reacts with rat renin (provided by Dr. D.J.
Campbell, Melbourne, Australia).
Results
The occurrence of the MH phenotype in male and female trans-
genie heterozygotes is given in Table 1, which shows a significantly
higher incidence in TGRIEdin heterozygotes than either TGR/
Han or TGR/Lew heterozygotes. The median age at the time of
death was 59 days (range 46 to 102 days).
Continuous recording of blood pressure in conscious TGR/Han
and TGRILew heterozygotes by telemetry showed development of
hypertension with a characteristic rise to a plateau by 70 days of
age with a MBP of 170 mm Hg (Fig. 1A). In contrast, those
TGR/Edin (7 out of 10) and TGR/Han (1 out of 12) that
developed MH while on telemetry showed a continuing increase
in blood pressure, which culminated in a terminal accelerated rise
of 67 to 75 mm Hg (mean 72 mm Hg) over six hours (Fig. 1B).
MBP in pre-malignant phase TGR/Edin was significantly higher
than either TGR/Han or TGRILew at 52 to 57 days of age, but by
75
days of age the MBP attained by TGR/Han and TGR!Lew hetero-
zygotes was not significantly different to pre-malignant phase
TGR/Edin (data not shown).
All animals that exhibited signs of the MH phenotype were
found to have pathological changes in the kidney. Figure 1C
shows a kidney section from an 8-week-old hypertensive, but not
malignant phase, transgenic rat kidney. In contrast, Figure 1D
shows changes of MH. Fibrinoid necrosis was seen to principally
affect afferent arterioles, interlobular arteries and occasional
portions of glomerular tufts. Secondary ischemic changes were
relatively rare, implying that such changes were acute. In addition
proliferative myointimal changes with endothelial swelling and
luminal thrombi were observed. More chronic hypertensive vas-
cular and glomerular changes were not seen in the age range of
the animals developing malignant phase hypertension. Small
myocardial microinfarcts were seen in many TGR/Edin that
developed MH, some in relation to fibrinoid changes within small
cardiac arterioles. Cerebrovascular pathology was infrequent, with
occasional infarction and hemorrhage. Minor thickening was seen
in mesenteric artery wall, but there was no difference between
malignant and non-malignant phenotypes.
The MH phenotype was associated with varying degrees of
renal failure with a mean creatinine of 111.9 .tmol/liter in
malignant TGR/Edin compared to 55 healthy age-matched hyper-
tensive heterozygotes (range 22.4 to 60.4 imol/liter, 95% confi-
dence limits). No significant difference in renal function was
observed between the transgenic heterozygote crosses prior to the
development of MH.
Significant elevation of PRA (29.1 11.0 vs. 9.2 8.3 ng Ang
I/ml/hr), Ang II (829.5 653.4 vs. 28.0 25.2 pg/mI) and
aldosterone (11.4 7.7 vs. 0.71 0.97 nmol/liter) were seen in
MH rats compared with age matched, non-malignant phase,
hypertensive transgenic heterozygotes (Results shown as mean
SD, N = 6 to 24 per group; P < 0.001). Immunohistochemical
labeling of kidney sections using a rabbit anti-mouse renin
antibody demonstrated a marked increase in renin staining at the
vascular poles in malignant hypertensives (not shown). Staining of
other renal structures was not found.
A small reduction in dietary sodium (0.2% vs. 0.32%) within the
'normal' range was given from weaning to transgenic heterozy-
gotes to mimic rat chow fed to original TGR/Han heterozygotes
when first established and studied in Department of Pharmacol-
ogy, University of Heidelberg, Germany [9]. There was a small
reduction in MBP in telemetered TGR/Han and TGR/Lewis (Fig.
2 A, B) which was only significant at 75 days in TGR/Han and 75
to 81 days in TGR/Lew. No significant differences in the occur-
rence of MH occurred, with one case in the TGR/Han group on
0.32% sodium diet, but none in either TGR/Lew group.
SBP measured by tail cuff plethysmography under light halo-
thane anaesthesia in non-transgenic Edinburgh SD and Hannover
SD (N = 6 to 14 per group) on a 0.32% Na diet from 4 to 12 weeks
of age showed a lower SBP in Edinburgh SD from six weeks of age
and slightly lower body weight (Fig. 2 C, D)
Discussion
The spontaneous occurrence of the MH phenotype in the
transgenic rat line TGR(mREN2)27 is associated with evidence of
classical pathological changes of fibrinoid necrosis and myo-
intimal proliferation, renal failure, evidence of renal RAS activation
and an accelerated rise in BP. Furthermore, the high percentage of
male TGR/Edin affected offers a potentially valuable animal model
in which to study MH, in particular the initiating and subsequent
events.
In this case transgenesis has created a monogenic model of
hypertension in which additional interactions, either environmen-
tal or genetic, have resulted in MH. What factors determine
susceptibility in humans are poorly understood. Cigarette smoking
[15, 16], oral contraceptive use [17] and HLA type have all been
implicated [18]. Environmental factors were questioned in view of
the change in phenotype on breeding TGR#27 heterozygotes in
Edinburgh as compared to Heidelberg. Analysis of rat chow
revealed a slightly higher sodium content in 'Scottish' rat chow,
but a comparison of the two diets did not significantly affect either
blood pressure or survival. No other environmental differences
such as temperature, humidity profiles or lighting times were
found to explain the phenotypic change. Furthermore, the high
incidence of MH in TGRIEdin compared with TGR/Han and
TGR/Lew when maintained in identical conditions and on the
same diet suggested that environmental factors were not crucial.
It is likely that genetic diversity within the SD strain, which is
outbred, explains the difference between Hannover and Edin-
burgh strains. The finding of a lower SBP in Edinburgh SD
compared with Hannover SD rats argues against additional
'hypertensive' genes contributing to the MH phenotype.
Neither the rate of rise in blood pressure nor absolute BP
appear to be important in determining the risk of onset of
malignant phase hypertension, but higher BP at a younger age
may be important in these rats. The continuing rise in BP during
IA1
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Fig. 1. Two examples of continuous recording of MBP by telemetiy show in (A), 'normal' hypertension reaching a plateau phase of 170 mm Hg in a TGR/Han,
and in (B), the terminal 40 hours of a 79 day old TGRIEdin with MH demonstrating the accelerated phase with a rise of 75 mm Hg in si hours. (C) A light
micrograph showing a normal glomerulus, afferent arteriole and interlobular artery (IA) from a non-malignant phase transgenic heterozygote. (D)
Myointimal proliferative changes (arrowed) and fibrinoid necrosis of interlobular arteries from a TGRIEdin with MH. (H&E stain X 100)
the accelerated phase may be due to loss of autoregulatory
mechanisms and the development of a high renin hypertension.
Initial characterization of the TGR(mREN2)27 rat line has
suggested that the hypertension may be Ang II dependent [19],
though there is evidence that altered adrenal steroid metabolism
may be important [20, 21]. Certainly transgenic rats with estab-
lished hypertension have evidence of a suppressed kidney RAS
[8]. In the malignant phase, activation of the renal RASwas seen
with increased immunohistochemical staining of the afferent
arteriole at the vascular pole. By the method used, we have not
differentiated mouse from rat renin, but would expect that as a
consequence of the relatively low level of transgene expression in
the kidney [8], that it is predominantly endogenous rat renin
which is expressed in the malignant hypertensive transgenic rat
kidney.
In conclusion, we believe that this may be a valuable animal
model in which it may be possible to identify factors, either
genetic or environmental, that contribute to the development of
malignant phase hypertension. It suggests that the target organ
damage resulting from hypertension in this case may in part be
dependent on the interaction of additional genetic factors.
Reprint requests to Dr. C.E. Whitworth, Centre for Genome Research,
University of Edinburgh, West Mains Road, Edinburgh EH9 3JQ, Scotland,
United Kingdom.
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Fig. 2. MBP (mm Hg) measured by telemetry in (A) TGR/Han (N = 6, 5) and (B) TGR/Lew heterozygotes (N = 4, 5) on 0.32% () and 0.2% (]) sodium diets,
respectively. Results are shown as mean so for each group. MBP for each animal is taken as the mean over the 24 hour period (recordings at 10 mm intervals).
*Significant difference (P < 0.05) in MBP arising between 0.32% and 0.2% sodium diets. (C) SBP (mm Hg) of Edinburgh SD (0) and Hannover SD (U) rats
from 4 to 12 weeks of age measured weekly by tail cuff plethysmography under light halothane anaesthesia; **SBP for Han SD > Edin SD (P < 0.05); (D)
body weight.
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